{"denoms":[{"counts":[{"groupId":"BG000","value":"189"}],"units":"Participants"}],"groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"BG000","title":"Blinatumomab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"18","upperLimit":"79","value":"39.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"90"}]}],"title":"18 to < 35 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"}]}],"title":"35 to < 55 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}]}],"title":"55 to < 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}],"title":"≥ 65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"119"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"145"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"American Indian or Alaska native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Native Hawaiian or other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Not recorded"}],"description":"Race was not permitted to be collected in France","paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"Primary refractory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"39"}]}],"title":"Relapse ≤ 12 months of allogeneic HSCT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}],"title":"Entering first salvage; first remission ≤ 12 mo"},{"categories":[{"measurements":[{"groupId":"BG000","value":"108"}]}],"title":"Entering second or greater salvage therapies"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"No criteria met"}],"description":"HSCT = hematopoietic stem cell transplantation","paramType":"NUMBER","title":"Disease stage entry criteria met","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"107"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"}]}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":">2"}],"paramType":"NUMBER","title":"Number of prior relapses","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64"}]}],"title":"Prior allogeneic HSCT"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"No prior alloHSCT, no prior relapse"},{"categories":[{"measurements":[{"groupId":"BG000","value":"84"}]}],"title":"No prior alloHSCT, 1 prior relapse"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"No prior alloHSCT, 2 prior relapses"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"No prior alloHSCT, > 2 prior relapses"}],"description":"alloHSCT = allogeneic hematopoietic stem cell transplantation","paramType":"NUMBER","title":"Prior allogeneic HSCT and prior relapses","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38"}]}],"title":"No prior salvage therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"77"}]}],"title":"1 prior salvage therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"42"}]}],"title":"2 prior salvage therapies"},{"categories":[{"measurements":[{"groupId":"BG000","value":"32"}]}],"title":"> 2 prior salvage therapies"}],"paramType":"NUMBER","title":"Number of prior salvage therapies","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1.9","upperLimit":"249.0","value":"16.59"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time since initial diagnosis","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.1","upperLimit":"56.8","value":"1.38"}]}]}],"description":"Reported for 173 participants with a prior relapse (the other16 participants were primary refractory with no prior relapses).","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time since last relapse","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"< 10%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"43"}]}],"title":"10% - < 50%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"145"}]}],"title":"≥ 50%"}],"description":"Bone marrow blasts were assessed by local and central laboratories; reported data are based on maximum central and local laboratory assessments.","paramType":"NUMBER","title":"Baseline bone marrow blast category","unitOfMeasure":"participants"}],"populationDescription":"Primary Analysis Set"}